Rep. Lisa C. McClain Purchases Shares of Repligen Corporation (NASDAQ:RGEN)

Posted by Casey Walker on Nov 27th, 2025

Representative Lisa C. McClain (R-Michigan) recently bought shares of Repligen Corporation (NASDAQ:RGEN). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in Repligen stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Repligen Stock Performance

NASDAQ:RGEN traded down $0.58 during midday trading on Thursday, reaching $171.18. 498,847 shares of the company traded hands, compared to its average volume of 823,434. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The company has a fifty day moving average price of $147.81 and a 200 day moving average price of $131.23. The firm has a market capitalization of $9.64 billion, a price-to-earnings ratio of 8,563.28, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15.

Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The business had revenue of $188.81 million during the quarter, compared to analyst estimates of $181.23 million. During the same quarter in the prior year, the firm earned $0.43 earnings per share. The company’s quarterly revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

A number of hedge funds have recently modified their holdings of the stock. Rhenman & Partners Asset Management AB boosted its holdings in shares of Repligen by 333.3% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the biotechnology company’s stock worth $2,425,000 after buying an additional 15,000 shares during the period. XTX Topco Ltd boosted its holdings in Repligen by 34.1% during the second quarter. XTX Topco Ltd now owns 17,352 shares of the biotechnology company’s stock valued at $2,158,000 after acquiring an additional 4,417 shares during the period. Harvest Fund Management Co. Ltd acquired a new stake in shares of Repligen in the first quarter valued at about $132,000. Congress Asset Management Co. increased its stake in shares of Repligen by 18.0% in the second quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock worth $18,962,000 after purchasing an additional 23,231 shares during the period. Finally, Dynamic Technology Lab Private Ltd lifted its position in shares of Repligen by 233.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company’s stock worth $1,172,000 after purchasing an additional 6,448 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on RGEN shares. HSBC began coverage on shares of Repligen in a research note on Wednesday, October 1st. They set a “buy” rating and a $150.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. Royal Bank Of Canada reiterated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research report on Tuesday, September 2nd. Weiss Ratings restated a “sell (d+)” rating on shares of Repligen in a report on Tuesday. Finally, Wells Fargo & Company decreased their target price on Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.85.

Check Out Our Latest Report on RGEN

Insider Buying and Selling

In related news, COO James Bylund sold 2,191 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the transaction, the chief operating officer directly owned 21,520 shares in the company, valued at $3,254,039.20. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Anthony Hunt sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the transaction, the director owned 80,743 shares in the company, valued at approximately $12,483,675.23. The trade was a 19.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 49,382 shares of company stock worth $7,676,802 in the last ninety days. Insiders own 1.20% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Repligen

(Get Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.